Top broker says Mesoblast shares can rocket 100%

Big returns could be on offer from this biotech according to Bell Potter.

| More on:
A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been a bruising ride for Mesoblast Ltd (ASX: MSB) shares in recent weeks, but if one leading broker is to be believed, the beaten-down biotech company could deliver some serious upside for investors.

That's the view of analysts at Bell Potter, which are feeling upbeat on the company's prospects now that its Ryoncil product has hit the market.

What is the broker say about Mesoblast shares?

According to the note, the main reason for the optimism is the launch of Mesoblast's lead product Ryoncil in the United States. The treatment, which targets steroid-refractory acute graft versus host disease (aGVHD) in children, is now commercially available, with the first patients treated in late March.

Bell Potter notes that key progress has been made on the reimbursement front. The product has now been included in the four major US drug pricing compendia, and the company has entered into a National Drug Rebate Agreement (NDRA) with Medicare. This opens the door to around 40% of the insured paediatric population in the US. It said:

Two recent announcements have progressed market access, these are: a) inclusion on the four major drug pricing compendia for the US – highly relevant for non-medicare patients; and b) the company has entered into the National Drug Rebate Agreement (NDRA) for Ryoncil, meaning that Medicare can now provide access to Ryoncil for the insured population i.e. ~40% of all children in the United States.

The NDRA should ensure that CMS pays the lowest rate in the market, hence our estimate for average revenue per patient of US$1.3m compared to the WAC price of US$1.55m.

Importantly, Mesoblast's commercial team will support each reimbursement claim on a payer-by-payer, state-by-state basis – not a small task but Bell Potter believes it will "minimise initial claim rejections by payers up to the point where the drug is recognised as mainstream."

No capital raise expected

Bell Potter believes that Mesoblast is well prepared financially for the launch. It highlights that the company has US$200 million in cash, which is "ample capital to support the launch." It also has around two years' worth of Ryoncil in storage, meaning production risk is low.

As a result, it feels that there is no need for Mesoblast to boost its cash balance further through a capital raise.

Big return potential

The note reveals that Bell Potter has retained its speculative buy rating on Mesoblast's shares with a reduced price target of $3.40.

Based on its current share price of $1.62, this implies potential upside of over 100% for investors over the next 12 months. Though, the broker concedes that it is a riskier option for investors and not suitable for everyone. It concludes:

In light of the modestly longer time to achieve patient access than previously contemplated, revenues in FY25 reduced by $11.6m. The key period is 1QCY26 – 9 months after launch by which time the majority of the US population should have reimbursement coverage. Valuation is reduced to $3.40 (from $4.10) following the rerating of global markets over recent days. Speculative stocks are limited to 100% upside from mkt price, hence the need to reduce the valuation.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »